Advertisement

Calcified Tissue International

, Volume 104, Issue 3, pp 235–238 | Cite as

Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  • J. A. Kanis
  • C. Cooper
  • R. RizzoliEmail author
  • J.-Y. Reginster
  • the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)
Review

Abstract

A guidance on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis was recently published in Osteoporosis International as a joint effort of the International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (Kanis et al. in Osteoporos Int  https://doi.org/10.1007/s00198-018-4704-5, 2018). This manuscript updates the previous guidelines document, published in 2013 (Kanis et al. in Osteoporos Int 24:23–57, 2013) and is written in a European perspective. The present article reports and summarizes the main recommendations included in this 2018 guidance document.

Keywords

Bone mineral density Diagnosis of osteoporosis Fracture risk assessment FRAX Health economics Treatment of osteoporosis 

Notes

Compliance with ethical standards

Conflict of interest

JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. JAK is the architect of FRAX® but has no financial interest. CC reports personal fees from Alliance for Better Bone Health,Amgen, Eli Lilly, GSK,Medtronic,Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, Nestlé, CNIEL and Sandoz. J-YR has received advisory board or consulting fees from IBSA-Genévrier, Pierre Fabre, Radius Health, TEVA and Mylan; and lecture fees from Anovos, IBSA-Genévrier, Mylan, CNIEL, Dairy Research Council (DRC) and Theramex; and institutional grant support from IBSA-Genévrier, Mylan, CNIEL and Radius Health.

References

  1. 1.
    Kanis JA, Cooper C, Rizzoli R, Reginster, JY on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors and the Committee of National Societies of the International Osteoporosis Foundation (IOF) (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int.  https://doi.org/10.1007/s00198-018-4704-5 Google Scholar
  2. 2.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 24: 23–57CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  • J. A. Kanis
    • 1
    • 2
  • C. Cooper
    • 3
    • 4
  • R. Rizzoli
    • 5
    Email author
  • J.-Y. Reginster
    • 6
    • 7
  • the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)
  1. 1.Centre for Metabolic Bone DiseasesUniversity of Sheffield, University of Sheffield Medical SchoolSheffieldUK
  2. 2.Mary McKillop Health InstituteAustralian Catholic UniversityMelbourneAustralia
  3. 3.MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK
  4. 4.NIHR Musculoskeletal Biomedical Research UnitUniversity of OxfordOxfordUK
  5. 5.Service of Bone Diseases, Faculty of Medicine of GenevaGeneva University HospitalsGeneva 14Switzerland
  6. 6.Prince Mutaib Chair for Biomarkers, College of ScienceKing Saud UniversityRiyadhSaudi Arabia
  7. 7.Department of Public Health, Epidemiology and Health EconomicsUniversity of LiègeLiègeBelgium

Personalised recommendations